Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).

Pestalozzi, Bernhard C; Tausch, Christoph; Dedes, Konstantin J; Rochlitz, Christoph; Zimmermann, Stefan; von Moos, Roger; Winterhalder, Ralph; Ruhstaller, Thomas; Mueller, Andreas; Buser, Katharina; Borner, Markus; Novak, Urban; Nussbaum, Catrina Uhlmann; Seifert, Bettina; Bigler, Martin; Bize, Vincent; Vilei, Simona Berardi; Rageth, Christoph; Aebi, Stefan (2017). Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). BMC cancer, 17(1), p. 265. BioMed Central 10.1186/s12885-017-3261-1

[img]
Preview
Text
Unbenannt.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (689kB) | Preview

BACKGROUND To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). METHODS SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-resection, ≥10% ER+ malignant cells, HER2-, pN0/pN1a. Patients were stratified into low-risk (LR) and non-low-risk (NLR) groups based on involved nodes (0 vs 1-3) and five additional predefined risk factors. Recommendations were classified as hormonal therapy (HT) or chemotherapy plus HT (CT + HT). Investigators were blinded to the statistical analysis plan. A 5%/10% rate of recommendation change in LR/NLR groups, respectively, was assumed independently of RS (null hypotheses). RESULTS Two hundred twenty two evaluable patients from 18 centers had TB recommendations before and after consideration of the RS result. A recommendation change occurred in 45 patients (23/154 (15%, 95% CI 10-22%) in the LR group and 22/68 (32%, 95% CI 22-45%) in the NLR group). In both groups the null hypothesis could be rejected (both p < 0.001). Specifically, in the LR group, only 5/113 (4%, 95% CI 1-10%) with HT had a recommendation change to CT + HT after consideration of the RS, while 18/41 (44%, 95% CI 28-60%) of patients initially recommended CT + HT were subsequently recommended only HT. In the NLR group, 3/19 (16%, 95% CI 3-40%) patients were changed from HT to CT + HT, while 19/48 (40%, 95% CI 26-55%) were changed from CT + HT to HT. CONCLUSION There was a significant impact of using the RS in the LR and the NLR group but only 4% of LR patients initially considered for HT had a recommendation change (RC); therefore these patients could forgo ODX testing. A RC was more likely for NLR patients considered for HT. Patients considered for HT + CT have the highest likelihood of a RC based on RS.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Borner, Markus and Novak, Urban

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1471-2407

Publisher:

BioMed Central

Language:

English

Submitter:

Nicole Corminboeuf

Date Deposited:

22 Mar 2018 09:44

Last Modified:

25 Mar 2018 03:20

Publisher DOI:

10.1186/s12885-017-3261-1

PubMed ID:

28407750

Uncontrolled Keywords:

Adjuvant treatment recommendation ER-positive early breast cancer Multigene expression profiling Oncotype DX Recurrence score

BORIS DOI:

10.7892/boris.111328

URI:

https://boris.unibe.ch/id/eprint/111328

Actions (login required)

Edit item Edit item
Provide Feedback